[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524891":3},{"organization":4,"armGroups":7,"interventions":91,"overallOfficials":103,"centralContacts":148,"locations":159,"responsibleParty":278,"collaborators":280,"id":343,"slug":344,"hasResults":345,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":345,"sex":351,"minAge":352,"maxAge":103,"enrollmentInfo":353,"targetDuration":103,"studyType":356,"phases":357,"briefSummary":359,"conditions":360,"keywords":103,"overallStatus":174,"whyStopped":103,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":371},{"fullName":5,"class":6},"University College, London","OTHER",[8,17,25,30,34,39,44,49,53,57,61,65,69,74,78,82,86],{"label":9,"type":10,"description":11,"interventionNames":12},"A. Standard TB Regimen. 2HRZE\u002F4HR","ACTIVE_COMPARATOR","24 weeks treatment in both Phase 2B and 2C - 8 weeks Rifampicin, Isoniazid, Pyrazinamide, Ethambutol followed by 16 weeks Rifampicin and Isoniazid.",[13,14,15,16],"Drug: Pyrazinamide (Z)","Drug: Rifampicin (R)","Drug: Isoniazid (H)","Drug: Ethambutol (E)",{"label":18,"type":19,"description":20,"interventionNames":21},"Arm B. BDM","EXPERIMENTAL","Bedaquiline, Delamanid, Moxifloxacin for 16 weeks in Phase 2B",[22,23,24],"Drug: Bedaquiline (B)","Drug: Delamanid (D)","Drug: Moxifloxacin (M)",{"label":26,"type":19,"description":27,"interventionNames":28},"Arm C. BDM + Gan","Bedaquiline, Delamanid, Moxifloxacin and Ganfeborole for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and Ganfeborole for 8-16 weeks in phase 2C",[29,22,23,24],"Drug: Ganfeborole",{"label":31,"type":19,"description":32,"interventionNames":33},"Arm D. BDZ + Gan","Bedaquiline, Delamanid, Pyrazinamide and Ganfeborole for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and Ganfeborole for 8-16 weeks in phase 2C",[29,22,23,13],{"label":35,"type":19,"description":36,"interventionNames":37},"Arm E. BDL + 656","Bedaquiline, Delamanid, Linezolid and Ganfeborole for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and Ganfeborole in Phase 2B Bedaquiline, Delamanid, Linezolid and Ganfeborole for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and Ganfeborole in Phase 2C",[29,22,23,38],"Drug: Linezolid (L)",{"label":40,"type":19,"description":41,"interventionNames":42},"Arm F. BPaM + Gan","Bedaquiline, Pretomanid, Moxifloxacin and Ganfeborole for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and Ganfeborolefor 8-16 weeks in Phase 2C",[29,22,43,24],"Drug: Pretomanid (Pa)",{"label":45,"type":19,"description":46,"interventionNames":47},"Arm G. BDM + BTZ-043","Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Moxifloxacin and BTZ-043 for 8-16 weeks in phase 2C",[48,22,23,24],"Drug: BTZ-043",{"label":50,"type":19,"description":51,"interventionNames":52},"Arm H. BDZ + BTZ-043","Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C",[48,22,23,13],{"label":54,"type":19,"description":55,"interventionNames":56},"Arm I. BDL + BTZ-043","Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2B Bedaquiline, Delamanid, Linezolid and BTZ-043 for 8 weeks followed by 0-8 weeks Bedaquiline, Delamanid and BTZ-043 in Phase 2C",[48,22,23,38],{"label":58,"type":19,"description":59,"interventionNames":60},"Arm J. BPaM + BTZ-043","Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Pretomanid, Moxifloxacin and BTZ-043 for 8-16 weeks in Phase 2C",[48,22,43,24],{"label":62,"type":19,"description":63,"interventionNames":64},"Arm K. BMZ + BTZ-043","Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Moxifloxacin, Pyrazinamide and BTZ-043 for 8-16 weeks in phase 2C",[48,22,24,13],{"label":66,"type":19,"description":67,"interventionNames":68},"Arm L. BD + Gan + BTZ-043","Bedaquiline, Delamanid, Ganfeborole and BTZ-043 for 16 weeks in Phase 2B Bedaquiline, Delamanid, Ganfeborole and BTZ-043 for 8-16 weeks in phase 2C",[29,48,22,23],{"label":70,"type":19,"description":71,"interventionNames":72},"Arm M: BDM + Q","Bedaquiline, delamanid, moxifloxacin, quabodepistat for 16 weeks in Phase 2B",[22,23,24,73],"Drug: Quabodepistat (Q)",{"label":75,"type":19,"description":76,"interventionNames":77},"Arm N: BPAM + Q","Bedaquiline, pretomanid, moxifloxacin, quabodepistat for 16 weeks in Phase 2B",[22,43,24,73],{"label":79,"type":19,"description":80,"interventionNames":81},"Arm O: BD + Gan + Q","Bedaquiline, delamanid, ganfeborole, quabodepistat for 16 weeks in Phase 2B",[29,22,23,73],{"label":83,"type":19,"description":84,"interventionNames":85},"Arm P: BPa + Gan +Q","Bedaquiline, pretomanid, ganfeborole, quabodepistat for 16 weeks in Phase 2B",[29,22,43,73],{"label":87,"type":19,"description":88,"interventionNames":89},"Arm Q: BPa + DZD + BTZ-043","Bedaquiline, pretomanid, delpazolid, BTZ-043 for 16 weeks in Phase 2B",[48,22,43,90],"Drug: Delpazolid (DZD)",[92,99,104,108,112,116,120,124,128,132,136,140,144],{"type":93,"name":94,"description":95,"armGroupLabels":96,"otherNames":97},"DRUG","Ganfeborole","Oral daily dosage of 20mg.",[26,31,35,40,66,79,83],[98],"GSK3036656",{"type":93,"name":100,"description":101,"armGroupLabels":102,"otherNames":103},"BTZ-043","Oral daily dosage of 1000mg.",[45,50,54,58,62,66,87],null,{"type":93,"name":105,"description":106,"armGroupLabels":107,"otherNames":103},"Bedaquiline (B)","Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.",[18,26,31,35,40,45,50,54,58,62,66,70,75,79,83,87],{"type":93,"name":109,"description":110,"armGroupLabels":111,"otherNames":103},"Delamanid (D)","Oral daily dosage of 300mg.",[18,26,31,35,45,50,54,66,70,79],{"type":93,"name":113,"description":114,"armGroupLabels":115,"otherNames":103},"Pretomanid (Pa)","Oral daily dosage of 200mg.",[40,58,75,83,87],{"type":93,"name":117,"description":118,"armGroupLabels":119,"otherNames":103},"Moxifloxacin (M)","Oral daily dosage of 400mg.",[18,26,40,45,58,62,70,75],{"type":93,"name":121,"description":122,"armGroupLabels":123,"otherNames":103},"Linezolid (L)","Oral daily dosage of 600mg for the first 8 weeks.",[35,54],{"type":93,"name":125,"description":126,"armGroupLabels":127,"otherNames":103},"Pyrazinamide (Z)","Oral daily dosage of 1200mg-2000mg depending on weight.",[9,31,50,62],{"type":93,"name":129,"description":130,"armGroupLabels":131,"otherNames":103},"Rifampicin (R)","Oral daily dosage of 450mg-750mg depending on weight.",[9],{"type":93,"name":133,"description":134,"armGroupLabels":135,"otherNames":103},"Isoniazid (H)","Oral daily dosage of 225mg-375mg depending on weight.",[9],{"type":93,"name":137,"description":138,"armGroupLabels":139,"otherNames":103},"Ethambutol (E)","Oral daily dosage of 825mg-1375mg depending on weight.",[9],{"type":93,"name":141,"description":142,"armGroupLabels":143,"otherNames":103},"Delpazolid (DZD)","Oral daily dosage of 1200mg",[87],{"type":93,"name":145,"description":146,"armGroupLabels":147,"otherNames":103},"Quabodepistat (Q)","Oral daily dosage of 30mg",[70,75,79,83],[149,155],{"name":150,"role":151,"phone":152,"phoneExt":153,"email":154},"Susie Slater","CONTACT","20 7670 4789","+44","mrcctu.paradigm4tb@ucl.ac.uk",{"name":156,"role":151,"phone":157,"phoneExt":153,"email":158},"Karen Sanders","2076704826","karen.sanders@ucl.ac.uk",[160,172,186,194,205,217,228,239,252,260,270],{"facility":161,"status":162,"city":163,"state":103,"zip":103,"country":164,"countryCode":165,"cosmosGeoPoint":166,"geoPoint":171,"contacts":103},"PMSI Institute of Pneumology \"Chiril Draganiuc\"","ACTIVE_NOT_RECRUITING","Chisinau","Moldova","MD",{"type":167,"coordinates":168},"Point",[169,170],28.85938,47.00902,{"lat":170,"lon":169},{"facility":173,"status":174,"city":175,"state":103,"zip":103,"country":176,"countryCode":177,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"TASK Brooklyn","RECRUITING","Cape Town","South Africa","ZA",{"type":167,"coordinates":179},[180,181],18.42322,-33.92584,{"lat":181,"lon":180},[184],{"name":185,"role":151,"phone":103,"phoneExt":103,"email":103},"Fairoez Ryklief",{"facility":187,"status":174,"city":175,"state":103,"zip":103,"country":176,"countryCode":177,"cosmosGeoPoint":188,"geoPoint":190,"contacts":191},"University of Cape Town Lung Institute",{"type":167,"coordinates":189},[180,181],{"lat":181,"lon":180},[192],{"name":193,"role":151,"phone":103,"phoneExt":103,"email":103},"Rodney Dawson",{"facility":195,"status":174,"city":196,"state":103,"zip":103,"country":176,"countryCode":177,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"TASK Eden","George",{"type":167,"coordinates":198},[199,200],22.46173,-33.963,{"lat":200,"lon":199},[203],{"name":204,"role":151,"phone":103,"phoneExt":103,"email":103},"Louis Botha",{"facility":206,"status":174,"city":207,"state":103,"zip":103,"country":208,"countryCode":103,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"NIMR Mbeya","Mbeya","Tanzania",{"type":167,"coordinates":210},[211,212],33.45,-8.9,{"lat":212,"lon":211},[215],{"name":216,"role":151,"phone":103,"phoneExt":103,"email":103},"Lilian Tina Minja",{"facility":218,"status":174,"city":219,"state":103,"zip":103,"country":208,"countryCode":103,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Kibong'oto Infectious Diseases Hospital","Moshi",{"type":167,"coordinates":221},[222,223],37.33333,-3.35,{"lat":223,"lon":222},[226],{"name":227,"role":151,"phone":103,"phoneExt":103,"email":103},"Stellah Mpagama",{"facility":229,"status":174,"city":230,"state":103,"zip":103,"country":208,"countryCode":103,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"NIMR Mwanza","Mwanza",{"type":167,"coordinates":232},[233,234],32.9,-2.51667,{"lat":234,"lon":233},[237],{"name":238,"role":151,"phone":103,"phoneExt":103,"email":103},"Kidola Jeremiah",{"facility":240,"status":174,"city":241,"state":103,"zip":103,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"Joint Clinical Research Centre","Kampala","Uganda","UG",{"type":167,"coordinates":245},[246,247],32.58219,0.31628,{"lat":247,"lon":246},[250],{"name":251,"role":151,"phone":103,"phoneExt":103,"email":103},"Cissy Kityo Mutuluuza",{"facility":253,"status":174,"city":241,"state":103,"zip":103,"country":242,"countryCode":243,"cosmosGeoPoint":254,"geoPoint":256,"contacts":257},"Makerere University Lung Institute",{"type":167,"coordinates":255},[246,247],{"lat":247,"lon":246},[258],{"name":259,"role":151,"phone":103,"phoneExt":103,"email":103},"Bruce Kirenga",{"facility":261,"status":162,"city":262,"state":103,"zip":103,"country":263,"countryCode":264,"cosmosGeoPoint":265,"geoPoint":269,"contacts":103},"National Lung Hospital","Hanoi","Vietnam","VN",{"type":167,"coordinates":266},[267,268],105.84117,21.0245,{"lat":268,"lon":267},{"facility":271,"status":162,"city":272,"state":103,"zip":103,"country":263,"countryCode":264,"cosmosGeoPoint":273,"geoPoint":277,"contacts":103},"Pnth\u002FOucru","Ho Chi Minh City",{"type":167,"coordinates":274},[275,276],106.62965,10.82302,{"lat":276,"lon":275},{"type":279,"investigatorFullName":103,"investigatorTitle":103,"investigatorAffiliation":103,"oldNameTitle":103,"oldOrganization":103},"SPONSOR",[281,283,285,287,289,292,294,296,298,300,302,304,306,308,311,313,315,317,319,321,323,325,327,330,333,335,337,339,341],{"name":282,"class":6},"Radboud University Medical Center",{"name":284,"class":6},"London School of Hygiene and Tropical Medicine",{"name":286,"class":6},"University of Oxford",{"name":288,"class":6},"Research Center Borstel",{"name":290,"class":291},"Lygature","UNKNOWN",{"name":293,"class":6},"TASK Applied Science",{"name":295,"class":6},"Università Vita-Salute San Raffaele",{"name":297,"class":291},"Helmholtz Zentrum Munchen",{"name":299,"class":6},"KNCV Tuberculosis Foundation",{"name":301,"class":291},"Critical Path Institute",{"name":303,"class":291},"European Lung Foundation",{"name":305,"class":6},"Instituto de Saude Publica da Universidade do Porto",{"name":307,"class":6},"University of Liverpool",{"name":309,"class":310},"Institut de Recherche pour le Developpement","OTHER_GOV",{"name":312,"class":6},"University of Hamburg-Eppendorf",{"name":314,"class":6},"University of California, San Francisco",{"name":316,"class":291},"TB Alliance",{"name":318,"class":6},"Find",{"name":320,"class":291},"University of Milano",{"name":322,"class":6},"University of St Andrews",{"name":324,"class":6},"Uppsala University",{"name":326,"class":6},"European Respiratory Society",{"name":328,"class":329},"Tuberculosis Network European Trialsgroup","NETWORK",{"name":331,"class":332},"Janssen, LP","INDUSTRY",{"name":334,"class":332},"Otsuka Pharmaceutical Development & Commercialization, Inc.",{"name":336,"class":6},"German Center for Infection Research",{"name":338,"class":6},"Ludwig-Maximilians - University of Munich",{"name":340,"class":6},"University of Cambridge",{"name":342,"class":332},"GlaxoSmithKline","100524891","phase-2-platform-assessing-regimens-and-durations-in-a-global-multisite-consortium-for-tb-100524891",false,"NCT06114628","Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","A Seamless Phase 2B\u002FC Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis","PARADIGM4TB","Inclusion Criteria:\n\n1. Age 18 years or above at screening (or above age of legal consent at screening, if this is higher than 18 years in the jurisdiction in which the study is taking place)\n2. Clinical evidence of active TB disease, meeting either or both of the following criteria:\n\n   * Symptoms consistent with pulmonary TB at screening AND\u002FOR\n   * Imaging findings consistent with active pulmonary TB on chest X-ray performed at screening or within 7 days prior to screening\n3. At least one sputum specimen produced at screening tested on Xpert MTB\u002FRIF Ultra that has:\n\n   * a semi-quantitative result of 'medium' or 'high' AND\n   * does not show rifampicin resistance\n4. Body weight within the range of 30 to 100kg and body mass index within the range of 15 to 40kg\u002Fm2\n5. Willing to comply with study visits, all study procedures and treatment observation\n6. Resident at a fixed address that is readily accessible for visiting, within feasible travelling distance to the site and likely to remain resident there for the duration of trial follow-up\n7. Has provided written informed consent\n\nExclusion Criteria:\n\n1. Taken more than 1 daily dose of medication with anti-tuberculous activity during the 14 days prior to randomisation (isoniazid, rifampicin, pyrazinamide, ethambutol; linezolid, moxifloxacin, levofloxacin or amikacin) (for Phase 2b and Phase 2c)\n2. Known isoniazid resistance (at sites where national isoniazid monoresistance is greater than 10% rapid testing at screening is mandated; at other sites rapid testing at screening is optional)\n3. Known or suspected extra-thoracic TB, miliary TB or disseminated TB (in the judgement of the investigator; note uncomplicated pleural effusion occupying \\\u003C50% of hemithorax or concomitant intra- or extra-thoracic lymphadenopathy are not exclusions)\n4. Severe clinical pulmonary TB e.g. respiratory failure or complications likely to require hospital admission in the opinion of the investigator\n5. Poor general condition (Karnofsky score ≤50) OR where any delay in treatment cannot be tolerated in the opinion of the investigator\n6. Active malignancy requiring systemic therapy, radiotherapy or palliative therapy\n7. History of myocardial infarction, coronary heart disease or congestive cardiac failure; long QT syndrome or clinically significant arrhythmias; pulmonary hypertension; any known congenital cardiac problems; family history of long QT syndrome or sudden death from unknown or cardiac related cause; uncontrolled arterial hypertension (not excluded if this is corrected prior to randomisation)\n8. Vitiligo\n9. History of seizure(s)\n10. Current tendinitis (any cause) or history of tendinopathy associated with fluoroquinolone use\n11. History of vascular aneurysm\n12. Symptomatic peripheral neuropathy causing greater than minimal interference with usual social and functional activities\n13. Current alcohol or illicit drug use sufficient to compromise the safety of the participant or research staff or compromise adherence to study procedures, in the opinion of the investigator\n14. Any current or recent use of amphetamines or methamphetamines, either reported or evident on toxicity screen, if performed\n15. Any other medically or socially significant condition (e.g. psychiatric illness, chronic diarrhoeal disease, metabolic condition, other cardiovascular disease not listed under criterion 7), that would, in the opinion of the investigator, compromise the participant's safety or outcome in the trial; or lead to poor compliance with study visits and protocol requirements; or compromise the interpretation of trial safety and efficacy endpoints\n16. Women who are currently pregnant or breast-feeding\n17. Women of childbearing potential unwilling or unable to use appropriate effective contraception during the study intervention period and for at least 14 days after the last dose of study intervention; and unwilling to commit to refrain from donating eggs (ova, oocytes) for the purpose of reproduction during this period; definitions of childbearing potential and appropriate effective contraception given below\\*\\*\n18. Men who are unwilling to use a condom during the study period and for at least 90 days after the last dose of study drug during any activity that allows for the passage of ejaculate to another person; and are unwilling to commit to refrain from donating fresh unwashed semen\n19. Known allergy to one or more of the study drugs\n20. Taking a concomitant medication that has a known or predicted interaction with any of the study drugs to which the participant might be randomised. The participant need not be excluded if:\n\n    1. the concomitant medication can be stopped or replaced with an alternative non-interacting medication, if needed AND\n    2. the investigator judges there to be no residual clinical risk to the participant after stopping the concomitant medication (taking into account the washout period of 5x the half-life of the concomitant medication and the duration of the effect of the interaction on levels of study medication)\n21. Taking a concomitant medication that is known to prolong the QTc interval. The participant need not be excluded if the concomitant medication can be stopped or replaced with an alternative medication, if needed, and the duration of the QTc prolongation is expected to resolve prior to dosing of study medication (taking into account the washout period of 5x the half-life of the concomitant medication)\n22. Treatment with any immunosuppressive drugs within the 2 weeks prior to screening (taking systemic corticosteroids for less than 5 consecutive days and stopped at or prior to screening are not an exclusion; topical or inhaled steroids that are taken at a dose below the threshold considered to have systemic immunosuppressive effects are not excluded)\n23. Participation in other clinical intervention trial with an investigational agent within 8 weeks prior to the first dosing day in this trial\n24. 12-lead ECGs at screening or at baseline shows QTcF \\>450ms (men) or \\>460ms (women) calculated by Fridericia's formula; and\u002For any other clinically significant abnormality such as arrhythmia or ischaemia\n25. Any of the following laboratory parameters at screening:\n\n    1. Haemoglobin \\\u003C 9g\u002Fdl\n    2. Platelet count \\\u003C 50 x 109 cells\u002FL\n    3. Absolute neutrophil count \\\u003C1000 cells\u002FμL\n    4. Creatinine clearance of \\\u003C75ml\u002Fmin, calculated using Cockcroft-Gault equation\\*\n    5. ALT or AST \\> 3 times the upper limit of normal\n    6. Total bilirubin \\> 1.5 times upper limit of normal\n    7. Serum potassium \\\u003C3.5 mmol\u002FL (not excluded if corrected to above this level)\n    8. Serum magnesium \\\u003C 0.70mmol\u002FL (not excluded if corrected to above this level)\n    9. Serum calcium (corrected for albumin level) \\\u003C 2.10 mmol\u002FL (not excluded if corrected to above this level)\n26. Hepatitis B surface antigen positive (known, or on a test performed at screening)\n27. HIV antibody positive (known, or on test performed at screening)\\*\n28. Known Hepatitis C virus infection (unless also known to have negative PCR test)\\*","ALL","18 Years",{"count":354,"type":355},2500,"ESTIMATED","INTERVENTIONAL",[358],"PHASE2","The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB). The standard treatment for TB takes 24 weeks and uses four drugs. The consortium want to find new treatments that are faster but just as safe and effective.\n\nIn the trial, two new drugs will be used, BTZ-043 and GSK3036656, along with the drugs that are already used to treat TB in a variety of combinations (11 different combinations initially). These new drugs have worked well in tests with animals and have reduced the amount of TB bacteria in people's sputum\u002Fphlegm when used alone for two weeks. These new drugs will be used in combination with other TB drugs for a longer time (up to 16 weeks) in people with TB. The UNITE4TB consortium want to see if they work well and are safe.\n\nThis trial will take place at sites across the world and will involve people with TB of the lungs that would usually respond well to the standard treatment. But the new treatments being tested might also work for people with drug resistant TB, that's harder to treat.\n\nThe trial has two parts. In the first part, different combinations of drugs will be tried on up to 700 people for 16 weeks. These combinations will be compared to the standard 24-week treatment to see which ones work the best and are safe.\n\nIn the second part, the best combinations from the first part will be taken to try to find out what the best length of time is to give the treatment for. These combinations will be tried on up to 1800 people giving them either 8, 10, 12, 14 or 16 weeks treatment. The investigators will follow these people for a total of 72 weeks to make sure the treatment is working.\n\nThe UNITE4TB consortium hope that this trial will find new treatments that are fast, safe, and effective for both regular TB and resistant TB. If it works, it can then be tested again in a bigger trial to be sure.",[361],"Pulmonary Tuberculosis","2025-09-30",{"date":364,"type":365},"2025-10-06","ACTUAL",{"date":367,"type":365},"2024-01-09",{"date":369,"type":355},"2027-08-11",{"name":5,"class":6},11]